BBNX vs DXCM
BBNX: Beta Bionics is a medical technology company developing automated insulin delivery systems to simplify diabetes management and improve patient outcomes. DXCM: Dexcom is a leading medical technology company specializing in continuous glucose monitoring (CGM) systems that help people with diabetes manage their condition with real-time data.
Side-by-side fundamentals
| Metric | BBNX | DXCM | Edge |
|---|---|---|---|
| Price as of 2026-07-31 close | $12.83 | $83.45 | |
| Market cap as of 2026-08-03 | $577M | $31.5B | |
| P/E as of 2026-08-03 | n/a | 36.06 | |
| PEG as of 2026-08-03 | n/a | 1.41 | |
| Net margin as of 2026-08-03 | -60.3% | +19.3% | DXCM higher |
| Gross margin as of 2026-08-03 | +57.1% | +63.4% | DXCM higher |
| Operating margin as of 2026-08-03 | -70.1% | +21.4% | DXCM higher |
| ROE as of 2026-08-03 | -23.0% | +33.8% | DXCM higher |
| ROA as of 2026-08-03 | -20.5% | +13.4% | DXCM higher |
| Debt / equity as of 2026-08-03 | 0.00 | 0.44 | BBNX lower |
| Revenue growth (YoY) as of 2026-08-03 | +56.6% | +16.1% | BBNX higher |
| Revenue CAGR (3y) SEC XBRL | +189.1% | +17.0% | BBNX higher |
| Beta as of 2026-08-03 | 1.66 | 0.78 | |
| 1-year return as of 2026-07-31 close | -23.6% | +3.3% | DXCM higher |
Fundamentals: market data, as of 2026-08-03. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-31.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.